Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Oncology›Condition·Updated Jun 24, 2026·v1

Cervical Cancer v2 Systemic Therapy

Cervical cancer systemic therapy is a setting-defined cascade: weekly cisplatin 40 mg/m² × 5–6 during EBRT for locally advanced disease (FIGO IB3–IVA), with nedaplatin/lobaplatin/carboplatin substitutes for renal impairment; no role for induction or adjuvant chemotherapy outside trials (OUTBACK, CALLA negative). For recurrent/metastatic disease, KEYNOTE-826 established pembrolizumab 200 mg Q3W plus platinum-taxane ± bevacizumab as first-line standard for PD-L1 CPS ≥1 (OS HR 0.64, NNT ≈ 9). Tisotumab vedotin 2 mg/kg Q3W is the preferred second-line option (innovaTV 301 OS HR 0.70, NNT ≈ 9), with mandatory ophthalmology prophylaxis for ocular toxicity. Emerging options — cadonilimab (PD-1/CTLA-4 bispecific), TROP-2 ADCs, TIL therapy, and HPV E6/E7 vaccines — remain investigational in 2026. Modern supportive care demands cycle-1 anticipation of organ-specific toxicities: pegfilgrastim for febrile neutropenia, enoxaparin for VTE on bevacizumab, methylprednisolone for grade ≥2 irAE pneumonitis, and duloxetine for chemotherapy-induced neuropathy.

High Evidence211 references·4,898 words·20 min read·v1
cervical cancersystemic therapychemoradiationcisplatinpembrolizumabbevacizumabtisotumab vedotinKEYNOTE-826innovaTV 301GOG 240JCOG0505OUTBACKCALLATACOimmunotherapyantibody-drug conjugategynecologic oncologyPD-L1 CPSlocally advanced cervical cancerrecurrent metastatic cervical cancer

Quick Reference

RxDrug of choicePembrolizumab 200 mg IV Q3W + cisplatin 50 mg/m² or carboplatin AUC 5 + paclitaxel 175 mg/m² ± bevacizumab 15 mg/kg for PD-L1 CPS ≥1 recurrent/metastatic disease (KEYNOTE-826); weekly cisplatin 40 mg/m² × 5–6 concurrent with EBRT for locally advanced disease
AltAlternativesNedaplatin 30 mg/m² IV weekly or lobaplatin 30 mg/m² IV q3W (renal-sparing for CRT); carboplatin AUC 5 Q3W (R/M if cisplatin-ineligible); tisotumab vedotin 2 mg/kg IV Q3W (second-line); cemiplimab or pembrolizumab monotherapy (PD-L1+ later lines)
⊘AvoidCarboplatin substitution when cisplatin is tolerable (inferior OS in JCOG0505); single-agent bevacizumab in chemo-eligible patients (GOG 240 benefit required combination chemo); tisotumab vedotin without baseline ophthalmology; pembrolizumab monotherapy first-line in PD-L1+ chemo-eligible patients
DxTest of choicePelvic MRI + PET-CT for staging; PD-L1 CPS for first-line pembrolizumab eligibility; eGFR + audiometry + CBC/CMP before each cisplatin cycle; tissue-factor IHC if tisotumab vedotin considered
ScKey scoreFIGO 2018 stage and ECOG performance status for initial stratification; PD-L1 CPS ≥1 for first-line immunotherapy benefit (KEYNOTE-826 OS HR 0.64); cisplatin-free interval >12 months predicts carboplatin non-inferiority
→When to referAll recurrent/metastatic patients to gynecologic oncology; clinical trial enrollment at any progression after first-line therapy; ophthalmology before tisotumab vedotin initiation; infectious disease for HIV-positive patients on antiretrovirals; palliative care at diagnosis of metastatic disease
Cervical cancer systemic therapy is setting-defined: weekly cisplatin 40 mg/m² × 5–6 concurrent with EBRT for locally advanced disease (NNT ≈ 17), pembrolizumab + platinum-taxane ± bevacizumab first-line for PD-L1 CPS ≥1 R/M disease (NNT ≈ 9), and tisotumab vedotin 2 mg/kg Q3W second-line after progression (NNT ≈ 9).
Cervical cancer systemic therapy is a setting-defined decision cascade, not a single regimen choice. Five clinical contexts shape management: radiosensitizing cisplatin with definitive [[external beam radiation therapy]] for locally advanced disease, adjuvant chemoradiation after radical hysterectomy, neoadjuvant/induction strategies still under investigation, first-line pembrolizumab plus platinum-taxane chemotherapy ± bevacizumab for recurrent/metastatic disease, and second-line tisotumab vedotin or cemiplimab after progression. The 2024 NCCN standard for PD-L1 CPS ≥1 recurrent/metastatic disease (KEYNOTE-826) added roughly 12 months of median overall survival, transforming first-line care. This page walks through each setting with specific doses, evidence-based alternatives, and modern biomarker-driven selection.

Overview and Recommendations

Setting-Based Framework

  • •Cervical cancer systemic therapy partitions into five distinct clinical settings — concurrent chemoradiation for , adjuvant therapy after radical hysterectomy, neoadjuvant/induction before definitive treatment, first-line for recurrent/metastatic disease, and subsequent lines after progression — and each carries its own randomized evidence backbone, drug selection, and biomarker implications.
  • •Concurrent cisplatin-based chemoradiation is the curative-intent standard for FIGO 2018 stages IB3–IVA and node-positive IB1 disease: cisplatin 40 mg/m² IV weekly for 5–6 cycles during EBRT (45–50.4 Gy) plus brachytherapy improves 5-year survival by ~6% (HR 0.83, 95% CI 0.77–0.90) compared with radiation alone, translating to an NNT ≈ 17 to prevent one death at 5 years across 18 randomized trials.
  • •Adjuvant chemotherapy after definitive chemoradiation does NOT improve overall survival — the OUTBACK trial (HR 0.91, 95% CI 0.77–1.07) closed the door on carboplatin/paclitaxel consolidation, reinforcing chemoradiation alone as the standard after radical hysterectomy for high-risk pathology (positive nodes, margins, parametria).
  • •Recurrent/metastatic first-line therapy was redefined by KEYNOTE-826: pembrolizumab 200 mg IV every 3 weeks added to platinum (cisplatin 50 mg/m² or carboplatin AUC 5) + paclitaxel 175 mg/m² ± bevacizumab 15 mg/kg improved median OS from 16.5 to 28.6 months (HR 0.64, 95% CI 0.50–0.81) in PD-L1 CPS ≥1 disease, an NNT ≈ 9 to prevent one death at 24 months.
  • •Bevacizumab was the first targeted agent to show an OS benefit (GOG 240: 17.0 vs 13.3 months, HR 0.77) and remains an additive option for symptomatic, bevacizumab-eligible patients, though the ESMO 2025 final analysis suggests equivalent survival whether or not it is added to pembrolizumab-chemotherapy.
  • •Tisotumab vedotin 2 mg/kg IV every 3 weeks is the preferred second-line option after first-line progression — the innovaTV 301 phase III trial showed median OS 11.5 vs 9.5 months (HR 0.70, 95% CI 0.54–0.90; NNT ≈ 9) versus investigator-choice chemotherapy, with a distinctive toxicity profile (ocular, neuropathy, hemorrhage) requiring mandatory prophylactic eye care.

Evaluation

  • •Staging with the FIGO 2018 system is the upstream decision node — clinical examination, pelvic MRI, and PET-CT define whether disease is locally advanced (IB3–IVA), node-positive IB1, or recurrent/metastatic, and each staging branch drives a different systemic therapy pathway.
  • •Order baseline CBC, comprehensive metabolic panel with , audiometry, and eGFR before initiating cisplatin — eGFR <60 mL/min, baseline hearing loss, or grade ≥2 neuropathy mandates substitution with nedaplatin, lobaplatin, or carboplatin depending on tolerance.
  • •Test PD-L1 with combined positive score ( ) on recurrent/metastatic disease biopsies — CPS ≥1 unlocks first-line pembrolizumab per KEYNOTE-826; CPS <1 patients may still benefit (HR 0.67 in subgroup analysis) but the FDA label restricts use to CPS ≥1.
  • •Assess MSI/MMR status to identify the small subset (~5%) eligible for pembrolizumab monotherapy under tissue-agnostic FDA approval, and reserve tissue-factor IHC for patients being considered for tisotumab vedotin in later lines.
  • •Determine bevacizumab eligibility before first-line therapy — exclude patients with recent fistula, major vessel involvement by tumor, uncontrolled hypertension (BP >160/90), or UPCR >1 g/24 h, as the risk of grade ≥3 fistula rises sharply with prior pelvic radiation and bowel/vaginal tumor involvement.
  • •Capture HIV status, CD4 count, and viral load — HIV is not a contraindication to modern systemic therapy including immune checkpoint inhibitors; well-controlled disease (CD4 ≥200 cells/µL, suppressed viral load) supports standard pembrolizumab-containing regimens with comparable outcomes.
  • •Evaluate performance status and geriatric parameters in patients ≥65 years — ECOG PS ≥2 is more decisive than chronological age; consider baseline geriatric assessment and prehabilitation before chemoradiation.
  • •Screen for peripheral neuropathy and ototoxicity at baseline and before each cisplatin cycle — grade ≥2 neuropathy or new tinnitus signals the need to substitute a renal-sparing platinum analog (nedaplatin, lobaplatin, or carboplatin AUC 2).
  • •Image with pelvic MRI ± PET-CT at 3 months post-CRT to identify treatment failure (residual signal) or persistent HPV ctDNA at week 5 — no salvage systemic regimen has demonstrated OS benefit in this setting; clinical trial enrollment is preferred.
  • •Confirm platinum-free interval when choosing first-line R/M chemotherapy — JCOG0505 showed carboplatin was non-inferior to cisplatin in platinum-naïve patients (HR 0.99) but inferior in those with prior platinum exposure within 12 months (HR 1.57).

Management

  • •Initiate concurrent cisplatin 40 mg/m² IV weekly × 5–6 cycles during EBRT 45–50.4 Gy followed by brachytherapy for FIGO 2018 IB3–IVA or node-positive IB1 disease — NCCN Category 1, NNT ≈ 17 to prevent one death at 5 years.
  • •Substitute nedaplatin 30 mg/m² IV weekly for renal impairment (eGFR 30–59 mL/min or mild neuropathy) — non-inferior OS with reduced nephro- and ototoxicity per a 2026 meta-analysis; lobaplatin 30 mg/m² IV q3W is an alternative in elderly patients with higher completion rates (83.9% vs 54.5% weekly cisplatin).
  • •Reserve carboplatin AUC 2 IV weekly for patients who cannot tolerate cisplatin or nedaplatin — inferior OS in JCOG0505 (HR 1.04), so do NOT substitute carboplatin when cisplatin is tolerable.
  • •Administer IV hydration (1 L NS pre- and post-infusion) with forced diuresis each cisplatin cycle; add NK1 + 5-HT3 + dexamethasone prophylaxis (e.g., fosaprepitant 150 mg IV day 1) to reduce emesis across the 5–6 week course.
  • •Initiate first-line pembrolizumab 200 mg IV every 3 weeks (up to 35 cycles) + platinum (cisplatin 50 mg/m² or carboplatin AUC 5) + paclitaxel 175 mg/m² IV every 3 weeks ± bevacizumab 15 mg/kg IV every 3 weeks for persistent, recurrent, or metastatic disease with PD-L1 CPS ≥1 (NCCN Category 1, KEYNOTE-826).
  • •Add bevacizumab 15 mg/kg IV Q3W when the patient is bev-eligible and disease is symptomatic or aggressive — expect ~25% grade ≥3 hypertension, ≤3% fistula/perforation, and elevated VTE risk; monitor BP and UPCR each cycle.
  • •Do NOT add induction or adjuvant chemotherapy outside a clinical trial — OUTBACK and the 2011 gemcitabine/cisplatin adjuvant trial were OS-negative with added toxicity; CALLA showed concurrent durvalumab during CRT missed its PFS endpoint (HR 0.84, 95% CI 0.65–1.08).
  • •Transition to tisotumab vedotin 2 mg/kg IV every 3 weeks on first-line progression — order baseline ophthalmology evaluation with topical steroid and mydriatic prophylaxis to mitigate ocular toxicity (~50–60% any-grade); reduce to 1.3 mg/kg for grade ≥3 ocular events.
  • •Consider pembrolizumab monotherapy in PD-L1-positive patients who did not receive it first-line (ORR ~17%, KEYNOTE-028), or cemiplimab per French 2024–2025 guidelines regardless of PD-L1 status; enroll in clinical trials for TROP-2 ADCs, cadonilimab (PD-1/CTLA-4 bispecific), or TIL therapy after second-line progression.
  • •Use pegfilgrastim 6 mg SC on day 2–3 for primary febrile neutropenia prophylaxis when risk exceeds 20%; observed rates are 8–14% on weekly cisplatin 40 mg/m² chemoradiation, supporting individualized rather than universal prophylaxis.
  • •Administer VTE prophylaxis with enoxaparin 40 mg SC daily in hospitalized or post-operative patients on bevacizumab; therapeutic anticoagulation for confirmed VTE.
  • •Manage chemotherapy-induced peripheral neuropathy with duloxetine 30–60 mg daily (strongest RCT support); reserve gabapentin 300 mg TID titrated to 1,800 mg/day or pregabalin 75 mg BID for radicular neuropathic pain.
  • •Treat grade ≥2 immune-mediated pneumonitis with methylprednisolone 1–2 mg/kg/day and admit; monitor TSH and LFTs each pembrolizumab cycle, and initiate levothyroxine for confirmed hypothyroidism.
  • •Refer all pregnant patients with cervical cancer to multidisciplinary tumor board — neoadjuvant platinum-based chemotherapy has been delivered in the second and third trimesters to defer definitive radiotherapy until fetal maturity.
  • •Maintain HIV-positive patients on antiretroviral therapy and proceed with standard systemic regimens when CD4 ≥200 cells/µL and viral load is suppressed; coordinate with infectious disease for drug-drug interactions with antiretrovirals.
  • •Avoid non-steroidal anti-inflammatory drugs and nephrotoxins throughout cisplatin therapy; do NOT initiate tisotumab vedotin without baseline ophthalmology, and do NOT use pembrolizumab monotherapy first-line when chemotherapy is tolerable.

Board Review — High Yield

  • •KEYNOTE-826 — Pembrolizumab + platinum-taxane ± bevacizumab is first-line standard for PD-L1 CPS ≥1 recurrent/metastatic cervical cancer; OS HR 0.64 in CPS ≥1, NNT ≈ 9 to prevent one death at 24 months.
  • •Concurrent cisplatin — Weekly cisplatin 40 mg/m² × 5–6 during EBRT improves 5-year OS by ~6% (HR 0.83) for FIGO IB3–IVA disease; NNT ≈ 17 to prevent one death at 5 years; do NOT add adjuvant carboplatin/paclitaxel (OUTBACK negative).
  • •TACO trial — Tri-weekly cisplatin 75 mg/m² × 3 is non-inferior to weekly 40 mg/m², giving scheduling flexibility without compromising efficacy.
  • •Tisotumab vedotin — Second-line standard after first-line progression (innovaTV 301): 2 mg/kg IV Q3W, OS HR 0.70 vs investigator-choice chemo; mandatory baseline ophthalmology with topical steroid/mydriatic prophylaxis for ~50–60% ocular toxicity.
  • •JCOG0505 — Carboplatin non-inferior to cisplatin in platinum-naïve R/M disease (HR 0.99) but inferior when prior platinum exposure <12 months (HR 1.57); do NOT substitute carboplatin for tolerable cisplatin in curative setting.
  • •GOG 240 — Bevacizumab 15 mg/kg Q3W added to platinum-taxane improved OS from 13.3 to 17.0 months (HR 0.77) in R/M disease; do NOT use single-agent bevacizumab — benefit required combination chemotherapy.
  • •CALLA trial — Concurrent durvalumab with CRT missed its PFS endpoint (HR 0.84, 95% CI 0.65–1.08); immune checkpoint inhibition added to definitive CRT remains investigational.
  • •HIV is not a contraindication — Pembrolizumab/cemiplimab ORR ~62% in Japanese PWH cohort with CD4 ≥200; survival gaps reflect treatment-delivery disparities, not biologic contraindication.
  • •Platinum analogs for renal impairment — Nedaplatin 30 mg/m² weekly and lobaplatin 30 mg/m² q3W are guideline-supported substitutes for cisplatin in LACC with reduced nephro/ototoxicity.
  • •AIDS-defining malignancy — Cervical cancer is one of three AIDS-defining cancers; PWH present roughly a decade earlier and often with advanced FIGO stage; well-controlled HIV supports standard systemic therapy including immunotherapy.

Deep Dive — Evidence Details

References

  1. [1]

    Koh WJ, Abu-Rustum NR, Bean S et al.. “Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659131 ↗

    L2GUIDELINECited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens
  2. [2]

    Reid E, Suneja G, Ambinder RF et al.. “Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30099375 ↗

    L2GUIDELINECited in: Setting-Based Framework, Toxicity and Supportive Care, Special Populations
  3. [3]

    Lorusso D, Colombo N, Dubot C et al.. “Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 39393777 ↗

    L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy, Special Populations
  4. [4]

    Mayadev J, Vázquez Limón JC, Ramírez Godinez FJ et al.. “Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40500687 ↗

    L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens
  5. [5]

    Cetina L, González-Enciso A, Cantú D et al.. “Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2-IIB cervical cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23609186 ↗

    L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT
  6. [6]

    Sehouli J, Runnebaum IB, Fotopoulou C et al.. “A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22357252 ↗

    L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens, Toxicity and Supportive Care
  7. [7]

    Lissoni AA, Colombo N, Pellegrino A et al.. “A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19181826 ↗

    L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens
  8. [8]

    . “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 19001332 ↗

    L2SR_OBSCited in: Setting-Based Framework, Chemotherapy Regimens
  9. [9]

    Kitagawa R, Katsumata N, Shibata T et al.. “Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732161 ↗

    L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens
  10. [10]

    Gupta S, Maheshwari A, Parab P et al.. “Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29432076 ↗

    L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens
  11. [11]

    Kenter GG, Greggi S, Vergote I et al.. “Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37656948 ↗

    L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens
  12. [12]

    Xia L, Zhang K, Tang Y et al.. “Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40561369 ↗

    L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens
  13. [13]

    Zhang J, Liu R, Wang S et al.. “Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40288679 ↗

    L2TRIAL_NONRANDOMCited in: Setting-Based Framework, Targeted and Immune Therapy
  14. [14]

    Lorusso D, Ferrandina G, Pignata S et al.. “Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19605508 ↗

    L2TRIAL_NONRANDOMCited in: Setting-Based Framework, Toxicity and Supportive Care
  15. [15]

    Katsumata N, Hirai Y, Kamiura S et al.. “Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21345941 ↗

    L2TRIAL_NONRANDOMCited in: Setting-Based Framework, Toxicity and Supportive Care, Special Populations
  16. [16]

    Thaker PH, Salani R, Brady WE et al.. “A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27998970 ↗

    L2TRIAL_NONRANDOMCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens
  17. [17]

    Zagouri F, Korakiti AM, Zakopoulou R et al.. “Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis.” Cancer treatment reviews (2019). PMID: 31442939 ↗

    L2SR_OBSCited in: Setting-Based Framework, Chemotherapy Regimens
  18. [18]

    Andrade MO, Al-Alam OCM, Kim HJS et al.. “Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis.” Cancer treatment reviews (2025). PMID: 40408847 ↗

    L2SR_OBSCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens
  19. [19]

    Tzioras S, Pavlidis N, Paraskevaidis E et al.. “Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis.” Cancer treatment reviews (2007). PMID: 17112673 ↗

    L2SR_OBSCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens
  20. [20]

    Petrelli F, Riboldi V, Bruschieri L et al.. “First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis.” Cancer treatment reviews (2025). PMID: 40086103 ↗

    L2SR_OBSCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens, Targeted and Immune Therapy
  21. [21]

    Azim HA, Peccatori FA, Pavlidis N. “Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors.” Cancer treatment reviews (2010). PMID: 20015593 ↗

    L2SR_OBSCited in: Setting-Based Framework, Targeted and Immune Therapy
  22. [22]

    Ryu SY, Nam BH, Kim MH et al.. “A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study.” ESMO open (2026). PMID: 41812622 ↗

    L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Toxicity and Supportive Care
  23. [23]

    Mileshkin LR, Moore KN, Barnes EH et al.. “Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2023). PMID: 37080223 ↗

    L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens, Special Populations
  24. [24]

    Monk BJ, Toita T, Wu X et al.. “Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.” The Lancet. Oncology (2023). PMID: 38039991 ↗

    L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens, Special Populations
  25. [25]

    Oaknin A, Moore K, Meyer T et al.. “Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.” The Lancet. Oncology (2024). PMID: 38608691 ↗

    L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens, Special Populations
  26. [26]

    Monk BJ, Tewari KS, Dubot C et al.. “Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Oncology (2023). PMID: 36878237 ↗

    L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy, Special Populations
  27. [27]

    Symonds RP, Gourley C, Davidson S et al.. “Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.” The Lancet. Oncology (2015). PMID: 26474517 ↗

    L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens, Special Populations
  28. [28]

    Colombo N, Dubot C, Lorusso D et al.. “Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.” The New England journal of medicine (2021). PMID: 34534429 ↗

    L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy, Toxicity and Supportive Care
  29. [29]

    Vergote I, González-Martín A, Fujiwara K et al.. “Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.” The New England journal of medicine (2024). PMID: 38959480 ↗

    L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens
  30. [30]

    Tewari KS, Monk BJ, Vergote I et al.. “Survival with Cemiplimab in Recurrent Cervical Cancer.” The New England journal of medicine (2022). PMID: 35139273 ↗

    L1RCTCited in: Setting-Based Framework, Toxicity and Supportive Care
  31. [31]

    Tewari KS, Sill MW, Long HJ et al.. “Improved survival with bevacizumab in advanced cervical cancer.” The New England journal of medicine (2014). PMID: 24552320 ↗

    L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens, Targeted and Immune Therapy, Toxicity and Supportive Care, Special Populations
  32. [32]

    Chung HC, Ros W, Delord JP et al.. “Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30943124 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Targeted and Immune Therapy, Toxicity and Supportive Care, Special Populations
  33. [33]

    Frenel JS, Le Tourneau C, O'Neil B et al.. “Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29095678 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy, Toxicity and Supportive Care
  34. [34]

    Vergote I, Van Nieuwenhuysen E, O'Cearbhaill RE et al.. “Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37651655 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy
  35. [35]

    Xu Q, Wang J, Sun Y et al.. “Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35192397 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Chemotherapy Regimens
  36. [36]

    Tewari KS, Colombo N, Monk BJ et al.. “Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.” JAMA oncology (2024). PMID: 38095881 ↗

    L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens, Targeted and Immune Therapy
  37. [37]

    Birrer M, Li G, Yunokawa M et al.. “Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 39052242 ↗

    L2RCTCited in: Setting-Based Framework
  38. [38]

    Tabernero J, Andre F, Blay JY et al.. “Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers.” ESMO open (2022). PMID: 35305400 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework
  39. [39]

    Pötter R, Tanderup K, Schmid MP et al.. “MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.” The Lancet. Oncology (2021). PMID: 33794207 ↗

    L2TRIAL_NONRANDOMCited in: Setting-Based Framework, Concurrent Chemotherapy with RT
  40. [40]

    Coleman RL, Lorusso D, Gennigens C et al.. “Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.” The Lancet. Oncology (2021). PMID: 33845034 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy, Special Populations
  41. [41]

    Gao X, Xu N, Li Z et al.. “Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.” The Lancet. Oncology (2023). PMID: 37797632 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Chemotherapy Regimens, Toxicity and Supportive Care, Special Populations
  42. [42]

    Li K, Chen J, Hu Y et al.. “Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial.” The Lancet. Oncology (2024). PMID: 38048802 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens
  43. [43]

    Youn JW, Hur SY, Woo JW et al.. “Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.” The Lancet. Oncology (2020). PMID: 33271094 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Targeted and Immune Therapy, Toxicity and Supportive Care
  44. [44]

    Penson RT, Huang HQ, Wenzel LB et al.. “Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).” The Lancet. Oncology (2015). PMID: 25638326 ↗

    L1TRIAL_NONRANDOMCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens, Targeted and Immune Therapy, Toxicity and Supportive Care
  45. [45]

    Mayadev JS, Enserro D, Lin YG et al.. “Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.” JAMA oncology (2020). PMID: 31774464 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Concurrent Chemotherapy with RT
  46. [46]

    Lan C, Zhang P, Zhao J et al.. “Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer.” Cancer discovery (2026). PMID: 41511850 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Chemotherapy Regimens
  47. [47]

    Xu Q, Deng Z, Liu J et al.. “Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer.” Cancer discovery (2026). PMID: 41297028 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Chemotherapy Regimens
  48. [48]

    Zhong J, Wu L, Song Z et al.. “TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.” Cancer cell (2025). PMID: 41135519 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Targeted and Immune Therapy
  49. [49]

    Han K, Fyles A, Shek T et al.. “A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 36037303 ↗

    L1RCTCited in: Setting-Based Framework
  50. [50]

    Abu-Rustum NR, Yashar CM, Arend R et al.. “NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 38081139 ↗

    L1OTHERCited in: Setting-Based Framework, Chemotherapy Regimens
  51. [51]

    Koh WJ, Greer BE, Abu-Rustum NR et al.. “Cervical Cancer, Version 2.2015.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25870376 ↗

    L1OTHERCited in: Setting-Based Framework, Chemotherapy Regimens
  52. [52]

    Moore DH. “Chemotherapy for advanced, recurrent, and metastatic cervical cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18267059 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework, Chemotherapy Regimens
  53. [53]

    Flint ML, Byrne ME, Friedman CF. “Locally Advanced Cervical Cancer: What is the Preferred Systemic Treatment?” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671446 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens, Targeted and Immune Therapy
  54. [54]

    Hong DS, Concin N, Vergote I et al.. “Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31796521 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy, Toxicity and Supportive Care
  55. [55]

    Lou H, Cai H, Huang X et al.. “Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38372727 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy
  56. [56]

    Oaknin A, Ghamande SA, Kasamatsu Y et al.. “Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38165683 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens
  57. [57]

    Feng J, Tang D, Wang J et al.. “SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35653122 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework
  58. [58]

    An J, Tang J, Li BX et al.. “Efficacy and Safety of the Anti-PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 36136294 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework
  59. [59]

    Papadopoulos KP, Johnson ML, Lockhart AC et al.. “First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31796520 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens
  60. [60]

    Mi X, Lin T, Zhu X et al.. “Efficacy and safety of cadonilimab for malignant solid tumor treatment: a systematic review and meta-analysis.” Frontiers in immunology (2026). PMID: 42292353 ↗

    L1SR_OBSCited in: Setting-Based Framework, Toxicity and Supportive Care
  61. [61]

    Zhang D, Meng Y, Dong X et al.. “Efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents in advanced cervical cancer: a systematic review and meta-analysis.” Frontiers in immunology (2026). PMID: 42253994 ↗

    L1SR_OBSCited in: Setting-Based Framework, Chemotherapy Regimens, Toxicity and Supportive Care
  62. [62]

    Wang X, Zhang Y, Wang C et al.. “Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy.” Frontiers in immunology (2026). PMID: 42079658 ↗

    L1SR_OBSCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy, Toxicity and Supportive Care
  63. [63]

    Zhou L, Sun C, Diao P et al.. “Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis.” Frontiers in immunology (2026). PMID: 41869324 ↗

    L1SR_OBSCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens, Toxicity and Supportive Care
  64. [64]

    Soonthornthum T, Arias-Pulido H, Joste N et al.. “Epidermal growth factor receptor as a biomarker for cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21325449 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework
  65. [65]

    Park JY, Kim DY, Kim JH et al.. “Management of occult invasive cervical cancer found after simple hysterectomy.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19858083 ↗

    L3OTHERCited in: Setting-Based Framework, Chemotherapy Regimens
  66. [66]

    Cho Y, Kim KH, Yoon HI et al.. “Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27502717 ↗

    L3OTHERCited in: Setting-Based Framework, Concurrent Chemotherapy with RT
  67. [67]

    Monk BJ, Colombo N, Tewari KS et al.. “First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37910822 ↗

    L1OTHERCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy
  68. [68]

    Schmid MP, Lindegaard JC, Mahantshetty U et al.. “Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36599120 ↗

    L2OTHERCited in: Setting-Based Framework
  69. [69]

    Lurain K. “Treating Cancer in People With HIV.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37267514 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework, Special Populations
  70. [70]

    Ogasawara A, Suzuki S, Oda K et al.. “Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).” Gynecologic oncology (2026). PMID: 42013608 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy, Toxicity and Supportive Care
  71. [71]

    Van Nieuwenhuysen E, Vergote I, Randall LM et al.. “Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.” Gynecologic oncology (2026). PMID: 42000372 ↗

    L4TRIAL_NONRANDOMCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy
  72. [72]

    Garcia J, Hurwitz HI, Sandler AB et al.. “Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.” Cancer treatment reviews (2020). PMID: 32335505 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy
  73. [73]

    Pectasides D, Kamposioras K, Papaxoinis G et al.. “Chemotherapy for recurrent cervical cancer.” Cancer treatment reviews (2008). PMID: 18657909 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens
  74. [74]

    Attademo L, Tuninetti V, Pisano C et al.. “Immunotherapy in cervix cancer.” Cancer treatment reviews (2020). PMID: 32827839 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework
  75. [75]

    Wenzel HHB, Olthof EP, Bekkers RLM et al.. “Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis - A review.” Cancer treatment reviews (2022). PMID: 34773774 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework, Concurrent Chemotherapy with RT
  76. [76]

    Ventriglia J, Paciolla I, Pisano C et al.. “Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.” Cancer treatment reviews (2017). PMID: 28800469 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework, Targeted and Immune Therapy
  77. [77]

    Tolcher A, Hamilton E, Coleman RL. “The evolving landscape of antibody-drug conjugates in gynecologic cancers.” Cancer treatment reviews (2023). PMID: 37023499 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework, Targeted and Immune Therapy
  78. [78]

    Monk BJ, Enomoto T, Kast WM et al.. “Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.” Cancer treatment reviews (2022). PMID: 35413489 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy
  79. [79]

    Gennigens C, Jerusalem G, Lapaille L et al.. “Recurrent or primary metastatic cervical cancer: current and future treatments.” ESMO open (2022). PMID: 36108558 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens, Targeted and Immune Therapy
  80. [80]

    Lowy DR, Herrero R, Hildesheim A. “Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging.” The Lancet. Oncology (2015). PMID: 25943067 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework, Targeted and Immune Therapy
  81. [81]

    Du Q, Liu Q, Zhou Y et al.. “Primary prophylaxis with pegylated G-CSF is associated with improved treatment completion and progression-free survival in locally advanced cervical cancer undergoing concurrent chemoradiotherapy: a retrospective cohort study.” Future oncology (London, England) (2026). PMID: 41930746 ↗

    L3COHORTCited in: Setting-Based Framework, Chemotherapy Regimens
  82. [82]

    Lheureux S, Butler MO, Clarke B et al.. “Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.” JAMA oncology (2018). PMID: 29145543 ↗

    L4OTHERCited in: Setting-Based Framework
  83. [83]

    Wang Y, Farmer M, Izaguirre EW et al.. “Association of Definitive Pelvic Radiation Therapy With Survival Among Patients With Newly Diagnosed Metastatic Cervical Cancer.” JAMA oncology (2018). PMID: 30054609 ↗

    L3OTHERCited in: Setting-Based Framework, Concurrent Chemotherapy with RT
  84. [84]

    . “Reducing cervical cancer mortality in India.” Cancer discovery (2013). PMID: 23847374 ↗

    L5OTHERCited in: Setting-Based Framework
  85. [85]

    Ishida S, McCormick F, Smith-McCune K et al.. “Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.” Cancer cell (2010). PMID: 20541702 ↗

    L5OTHERCited in: Setting-Based Framework, Concurrent Chemotherapy with RT
  86. [86]

    . “Strong HPV Vaccine Response Predicts Better Survival with Chemotherapy.” Cancer discovery (2020). PMID: 32220926 ↗

    L5OTHERCited in: Setting-Based Framework
  87. [87]

    Chen Y, Liu L, Chen Y et al.. “Prognostic factors influencing the cure rate of 5-Aminolevulinic acid photodynamic therapy (ALA-PDT) of High-grade squamous intraepithelial lesions (HSIL): A retrospective cohort study.” Photodiagnosis and photodynamic therapy (2026). PMID: 41941918 ↗

    L3COHORTCited in: Setting-Based Framework
  88. [88]

    Friedman CF, Ravichandran V, Miller K et al.. “Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37643132 ↗

    L2OTHERCited in: Setting-Based Framework
  89. [89]

    Bonfill-Teixidor E, Neva-Alejo A, Arias A et al.. “Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39078728 ↗

    L5OTHERCited in: Setting-Based Framework
  90. [90]

    Lyng H, Skipar K, Hompland T. “Targeted Therapy on the Screen: Do We Hit the Target?” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 36240006 ↗

    L5OTHERCited in: Setting-Based Framework
  91. [91]

    Tewari KS, Monk BJ. “New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25104084 ↗

    L5REVIEW_NARRATIVECited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy
  92. [92]

    Sannigrahi MK, Sharma R, Singh V et al.. “Role of Host miRNA Hsa-miR-139-3p in HPV-16-Induced Carcinomas.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28143871 ↗

    L5OTHERCited in: Setting-Based Framework, Concurrent Chemotherapy with RT
  93. [93]

    Cantidio FS, Costa Diniz PH, Gil G et al.. “Bone marrow-sparing radiotherapy in women with cervical cancer treated with radiochemotherapy.” The Cochrane database of systematic reviews (2026). PMID: 42273975 ↗

    L1SR_OBSCited in: Setting-Based Framework
  94. [94]

    Yao H, Hao Z, Zhang X et al.. “Severe immune checkpoint inhibitor-induced 3M syndrome: a case report.” Frontiers in immunology (2026). PMID: 42292465 ↗

    L4CASE_REPORTCited in: Setting-Based Framework
  95. [95]

    Lin J, He H, Liu B et al.. “The exploration of iparomlimab and tuvonralimab combined with de-escalated chemotherapy as an innovative neoadjuvant treatment strategy for locally advanced cervical cancer: a case report from the NICE-CC trial.” Frontiers in immunology (2026). PMID: 42112362 ↗

    L4CASE_REPORTCited in: Setting-Based Framework, Chemotherapy Regimens
  96. [96]

    Gosecka M, Gosecki M, Urbaniak M et al.. “Unimolecular micelles as an effective carrier of poorly water-soluble nifuratel for selective in vivo anticervical cancer therapy via mucoadhesive dynamic hydrogels.” Journal of materials chemistry. B (2026). PMID: 42300096 ↗

    L5OTHERCited in: Setting-Based Framework
  97. [97]

    Koh WJ, Greer BE, Abu-Rustum NR et al.. “Cervical cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23486458 ↗

    L1GUIDELINECited in: Concurrent Chemotherapy with RT
  98. [98]

    Ryu SY, Deng W, Albuquerque K et al.. “Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40947016 ↗

    L1RCTCited in: Concurrent Chemotherapy with RT
  99. [99]

    Sugiyama T, Fujiwara K, Ohashi Y et al.. “Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24569914 ↗

    L1RCTCited in: Concurrent Chemotherapy with RT, Toxicity and Supportive Care
  100. [100]

    da Costa SCS, Bonadio RC, Gabrielli FCG et al.. “Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31449470 ↗

    L1RCTCited in: Concurrent Chemotherapy with RT
  101. [101]

    Dueñas-González A, Zarbá JJ, Patel F et al.. “Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21444871 ↗

    L1RCTCited in: Concurrent Chemotherapy with RT
  102. [102]

    Zuliani AC, Esteves SC, Teixeira LC et al.. “Concomitant cisplatin plus radiotherapy and high-dose-rate brachytherapy versus radiotherapy alone for stage IIIB epidermoid cervical cancer: a randomized controlled trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 24449243 ↗

    L1RCTCited in: Concurrent Chemotherapy with RT, Toxicity and Supportive Care
  103. [103]

    Rose PG, Ali S, Watkins E et al.. “Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17502627 ↗

    L1RCTCited in: Concurrent Chemotherapy with RT, Toxicity and Supportive Care
  104. [104]

    Yang X, Ren H, Li Z et al.. “A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer.” ESMO open (2022). PMID: 35994789 ↗

    L1RCTCited in: Concurrent Chemotherapy with RT
  105. [105]

    Ruhlmann CH, Christensen TB, Dohn LH et al.. “Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.” The Lancet. Oncology (2016). PMID: 26952945 ↗

    L1RCTCited in: Concurrent Chemotherapy with RT, Toxicity and Supportive Care
  106. [106]

    Huang H, Feng YL, Wan T et al.. “Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial.” JAMA oncology (2021). PMID: 33443541 ↗

    L1RCTCited in: Concurrent Chemotherapy with RT, Chemotherapy Regimens
  107. [107]

    Cho WK, Park W, Kim SW et al.. “Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer: The POHIM-CCRT Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 38662364 ↗

    L2RCTCited in: Concurrent Chemotherapy with RT
  108. [108]

    Tewari KS, Sill MW, Monk BJ et al.. “Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26672085 ↗

    L2RCTCited in: Concurrent Chemotherapy with RT, Chemotherapy Regimens, Targeted and Immune Therapy, Special Populations
  109. [109]

    Marchetti C, Fagotti A, Tombolini V et al.. “Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis.” Cancer treatment reviews (2020). PMID: 31838220 ↗

    L1SR_OBSCited in: Concurrent Chemotherapy with RT
  110. [110]

    Corbeau A, Spampinato S, Charnalia M et al.. “Normal tissue complication probability models for gastrointestinal toxicity after adjuvant (chemo)radiotherapy for cervical cancer in the PARCER trial.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 41698508 ↗

    L2RCTCited in: Concurrent Chemotherapy with RT
  111. [111]

    Hu L, Li J, Du Y et al.. “Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study.” Journal of gynecologic oncology (2026). PMID: 41381401 ↗

    L1RCTCited in: Concurrent Chemotherapy with RT, Chemotherapy Regimens
  112. [112]

    Dyer BA, Zamarin D, Eskandar RN et al.. “Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659133 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemotherapy with RT, Targeted and Immune Therapy
  113. [113]

    Xiang M, Kidd EA. “Benefit of Cisplatin With Definitive Radiotherapy in Older Women With Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31390586 ↗

    L2OTHERCited in: Concurrent Chemotherapy with RT, Toxicity and Supportive Care
  114. [114]

    Kidd EA, Grigsby PW. “Intratumoral metabolic heterogeneity of cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18698042 ↗

    L2TRIAL_NONRANDOMCited in: Concurrent Chemotherapy with RT
  115. [115]

    Nogueira-Rodrigues A, do Carmo CC, Viegas C et al.. “Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18829516 ↗

    L4TRIAL_NONRANDOMCited in: Concurrent Chemotherapy with RT, Chemotherapy Regimens
  116. [116]

    Kunos CA, Waggoner S, von Gruenigen V et al.. “Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20145183 ↗

    L4TRIAL_NONRANDOMCited in: Concurrent Chemotherapy with RT, Chemotherapy Regimens
  117. [117]

    Tewari KS. “Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31026210 ↗

    L5CASE_REPORTCited in: Concurrent Chemotherapy with RT, Chemotherapy Regimens
  118. [118]

    . “Prophylactic para-aortic irradiation vs pelvic radiotherapy in pelvic node-positive carcinoma cervix in the setting of concurrent chemoradiation: a phase II open-label multi centric randomized controlled trial (PRO-PARA).” Trials (2026). PMID: 41792812 ↗

    L5RCTCited in: Concurrent Chemotherapy with RT
  119. [119]

    Chargari C, Martinez A, Michels J et al.. “[French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of localized cervical cancer].” Bulletin du cancer (2026). PMID: 41617621 ↗

    L1GUIDELINECited in: Concurrent Chemotherapy with RT
  120. [120]

    Dryden-Peterson S, Bvochora-Nsingo M, Suneja G et al.. “HIV Infection and Survival Among Women With Cervical Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27573661 ↗

    L2OTHERCited in: Concurrent Chemotherapy with RT, Special Populations
  121. [121]

    Long HJ. “Management of metastatic cervical cancer: review of the literature.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17617528 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemotherapy with RT, Chemotherapy Regimens
  122. [122]

    Wei S, Li X, Liu Z et al.. “Nimotuzumab plus concurrent chemoradiotherapy sequential maintenance treatment for locally advanced cervical squamous cell carcinoma (NOTABLE-306): a multicenter, prospective, randomized, double-blind, placebo-controlled trial.” Journal of gynecologic oncology (2026). PMID: 41514314 ↗

    L5TRIAL_NONRANDOMCited in: Concurrent Chemotherapy with RT
  123. [123]

    Yokoi A, Machida H, Okazawa-Sakai M et al.. “Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis.” International journal of clinical oncology (2026). PMID: 42012622 ↗

    L1SR_OBSCited in: Concurrent Chemotherapy with RT
  124. [124]

    Umemiya M, Kou K, Inayama Y et al.. “Comparison of nedaplatin and cisplatin in concurrent chemoradiotherapy for cervical cancer: a systematic review and meta-analysis.” International journal of clinical oncology (2026). PMID: 41612081 ↗

    L1SR_OBSCited in: Concurrent Chemotherapy with RT, Toxicity and Supportive Care
  125. [125]

    Piya IJ, Riya IJ, Sharma V. “Efficacy and safety of immune checkpoint inhibitors with chemoradiotherapy/chemotherapy in locally advanced cervical cancer patients: a systematic review and single-arm meta-analysis.” Journal of gynecologic oncology (2026). PMID: 41267534 ↗

    L2SR_OBSCited in: Concurrent Chemotherapy with RT, Toxicity and Supportive Care
  126. [126]

    Wieringa HW, van der Zee AG, de Vries EG et al.. “Breaking the DNA damage response to improve cervical cancer treatment.” Cancer treatment reviews (2016). PMID: 26643553 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemotherapy with RT
  127. [127]

    Cabel L, Bonneau C, Bernard-Tessier A et al.. “HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer.” ESMO open (2021). PMID: 34022731 ↗

    L2OTHERCited in: Concurrent Chemotherapy with RT
  128. [128]

    Gouy S, Morice P, Narducci F et al.. “Nodal-staging surgery for locally advanced cervical cancer in the era of PET.” The Lancet. Oncology (2012). PMID: 22554549 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemotherapy with RT
  129. [129]

    Westerveld H, Nesvacil N, Fokdal L et al.. “Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer.” The Lancet. Oncology (2020). PMID: 32135119 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemotherapy with RT
  130. [130]

    Agustí N, Viveros-Carreño D, Wu CF et al.. “Adjuvant Chemoradiotherapy vs Radiotherapy Alone for Patients With Intermediate-Risk Cervical Cancer.” JAMA oncology (2025). PMID: 40079948 ↗

    L2OTHERCited in: Concurrent Chemotherapy with RT
  131. [131]

    Zhao X, Singhal A, Park S et al.. “Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress.” Cancer discovery (2024). PMID: 38236062 ↗

    L5OTHERCited in: Concurrent Chemotherapy with RT
  132. [132]

    Mondini M, Deutsch E. “(Chemo)Radiotherapy-Immunotherapy Combinations: Time to Get Tailored?” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33986023 ↗

    L5OTHERCited in: Concurrent Chemotherapy with RT, Targeted and Immune Therapy
  133. [133]

    Seo A, Xiao W, Gjyshi O et al.. “Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39680029 ↗

    L2OTHERCited in: Concurrent Chemotherapy with RT
  134. [134]

    Chaudary N, Pintilie M, Jelveh S et al.. “Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 27697997 ↗

    L5OTHERCited in: Concurrent Chemotherapy with RT
  135. [135]

    O'Malley DM, Neffa M, Monk BJ et al.. “Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 34932394 ↗

    L4TRIAL_NONRANDOMCited in: Chemotherapy Regimens
  136. [136]

    Yonemori K, Nishio S, Suzuki S et al.. “Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 41644383 ↗

    L1RCTCited in: Chemotherapy Regimens
  137. [137]

    Jones R, Plummer R, Moreno V et al.. “A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36378548 ↗

    L4TRIAL_NONRANDOMCited in: Chemotherapy Regimens
  138. [138]

    Kelly RJ, Draper D, Chen CC et al.. “A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 21081657 ↗

    L4TRIAL_NONRANDOMCited in: Chemotherapy Regimens
  139. [139]

    Zhou J, Ye W, Ranarisoa SN et al.. “Comparison of drug regimens for recurrent or metastatic cervical cancer: a systematic review and network meta-analysis.” Frontiers in immunology (2026). PMID: 41822503 ↗

    L1SR_OBSCited in: Chemotherapy Regimens, Targeted and Immune Therapy
  140. [140]

    Sabatier R, Hennequin C, Martin-Babau J et al.. “[French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of advanced cervical cancer].” Bulletin du cancer (2026). PMID: 41620326 ↗

    L1GUIDELINECited in: Chemotherapy Regimens
  141. [141]

    Liu Y, Ren T, Wang X et al.. “Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis.” Frontiers in oncology (2025). PMID: 41669254 ↗

    L1SR_OBSCited in: Chemotherapy Regimens
  142. [142]

    Monk BJ, Tewari KS, Koh WJ. “Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17617527 ↗

    L5REVIEW_NARRATIVECited in: Chemotherapy Regimens
  143. [143]

    Ismaili N. “Major Advances in Gynecologic Oncology in 2025: Systematic Review and Synthesis of Conference and Published Evidence.” Biomedicines (2026). PMID: 41751194 ↗

    L1SR_OBSCited in: Chemotherapy Regimens
  144. [144]

    Mountzios G, Soultati A, Pectasides D et al.. “Developments in the systemic treatment of metastatic cervical cancer.” Cancer treatment reviews (2013). PMID: 22727690 ↗

    L5REVIEW_NARRATIVECited in: Chemotherapy Regimens
  145. [145]

    Vora C, Gupta S. “Targeted therapy in cervical cancer.” ESMO open (2018). PMID: 30997156 ↗

    L5OTHERCited in: Chemotherapy Regimens
  146. [146]

    Sun Y, Yang H, Wang J et al.. “Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.” Nature communications (2026). PMID: 41826281 ↗

    L1RCTCited in: Chemotherapy Regimens, Targeted and Immune Therapy
  147. [147]

    Riggenbach E, Mose L, Imboden S et al.. “Intensified radiochemotherapy with cisplatin and gemcitabine for cervical cancer in the modern era: a retrospective cohort study.” Journal of gynecologic oncology (2026). PMID: 41413788 ↗

    L3COHORTCited in: Chemotherapy Regimens
  148. [148]

    Zhou J, Cai J, Li X et al.. “Pelvic radiotherapy combined with immunotherapy and chemotherapy for stage IVB cervical cancer: a retrospective study.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 41411697 ↗

    L3COHORTCited in: Chemotherapy Regimens
  149. [149]

    . “FDA Approves First Biosimilar to Treat Cancer.” Cancer discovery (2017). PMID: 28982661 ↗

    L5OTHERCited in: Chemotherapy Regimens, Targeted and Immune Therapy
  150. [150]

    Nakashima T, Matsumoto K, Yoshitake T et al.. “Impact of high-dose pelvic radiotherapy combined with chemotherapy on local control, symptom relief, and safety in patients with stage IVB cervical cancer (FIGO 2018): a two-center retrospective study.” Japanese journal of radiology (2026). PMID: 41441948 ↗

    L3COHORTCited in: Chemotherapy Regimens
  151. [151]

    Rotman J, Heeren AM, Gassama AA et al.. “Adenocarcinoma of the Uterine Cervix Shows Impaired Recruitment of cDC1 and CD8+ T Cells and Elevated β-Catenin Activation Compared with Squamous Cell Carcinoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32220890 ↗

    L2OTHERCited in: Chemotherapy Regimens
  152. [152]

    Wiwekananda IGNA, Malek NANN, Endharti AT et al.. “Nab-paclitaxel for the treatment of cervical cancer: a systematic review of clinical safety and effectiveness.” Journal of chemotherapy (Florence, Italy) (2026). PMID: 41655064 ↗

    L2SR_OBSCited in: Chemotherapy Regimens
  153. [153]

    Li H, Wu M, Xing Y et al.. “Sacituzumab govitecan combined with tislelizumab as second-line therapy for recurrent or metastatic cervical cancer: a case report and literature review.” BMC women's health (2026). PMID: 42015186 ↗

    L4CASE_REPORTCited in: Chemotherapy Regimens, Targeted and Immune Therapy
  154. [154]

    Chang HA, Armenian SH, Dellinger TH. “Secondary Neoplasms of the Female Lower Genital Tract After Hematopoietic Cell Transplantation.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29439180 ↗

    L2SR_OBSCited in: Targeted and Immune Therapy
  155. [155]

    Monk BJ, Sill MW, Burger RA et al.. “Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19139430 ↗

    L4TRIAL_NONRANDOMCited in: Targeted and Immune Therapy, Toxicity and Supportive Care, Special Populations
  156. [156]

    Lu YC, Parker LL, Lu T et al.. “Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28809608 ↗

    L4TRIAL_NONRANDOMCited in: Targeted and Immune Therapy, Toxicity and Supportive Care
  157. [157]

    Stevanović S, Helman SR, Wunderlich JR et al.. “A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30518633 ↗

    L4TRIAL_NONRANDOMCited in: Targeted and Immune Therapy
  158. [158]

    Welters MJ, Kenter GG, Piersma SJ et al.. “Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18172269 ↗

    L4TRIAL_NONRANDOMCited in: Targeted and Immune Therapy
  159. [159]

    Kenter GG, Welters MJ, Valentijn AR et al.. “Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18172268 ↗

    L4TRIAL_NONRANDOMCited in: Targeted and Immune Therapy
  160. [160]

    Basu P, Malvi SG, Joshi S et al.. “Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.” The Lancet. Oncology (2021). PMID: 34634254 ↗

    L2COHORTCited in: Targeted and Immune Therapy
  161. [161]

    Menicagli D, Casigliani V, Panizza F et al.. “HPVoice: a single-blind three-arm RCT on social media communication strategies among adolescents in Tuscany, Italy.” Vaccine (2026). PMID: 41855647 ↗

    L1RCTCited in: Targeted and Immune Therapy
  162. [162]

    Xu MA, Pant S, DiClemente RJ. “Factors affecting human papillomavirus vaccination: A review of individual, interpersonal, and structural factors affecting vaccine uptake among adolescents.” Vaccine (2026). PMID: 41965976 ↗

    L2SR_OBSCited in: Targeted and Immune Therapy
  163. [163]

    Xiao C, Zeng S, Li L et al.. “Efficacy and safety of immune checkpoint inhibitors combined with chemoradiotherapy in locally advanced cervical cancer: a systematic review and meta-analysis.” Frontiers in pharmacology (2026). PMID: 41859340 ↗

    L1SR_OBSCited in: Targeted and Immune Therapy
  164. [164]

    Giannone G, Giuliano AR, Bandini M et al.. “HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage.” Cancer treatment reviews (2022). PMID: 36265336 ↗

    L5REVIEW_NARRATIVECited in: Targeted and Immune Therapy
  165. [165]

    Sankaranarayanan R, Basu P, Kaur P et al.. “Current status of human papillomavirus vaccination in India's cervical cancer prevention efforts.” The Lancet. Oncology (2019). PMID: 31674322 ↗

    L5REVIEW_NARRATIVECited in: Targeted and Immune Therapy
  166. [166]

    Vaccarella S, Franceschi S, Zaridze D et al.. “Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017-40: a population-based study.” The Lancet. Oncology (2016). PMID: 27567054 ↗

    L2OTHERCited in: Targeted and Immune Therapy
  167. [167]

    Lei J, Ploner A, Elfström KM et al.. “HPV Vaccination and the Risk of Invasive Cervical Cancer.” The New England journal of medicine (2020). PMID: 32997908 ↗

    L2OTHERCited in: Targeted and Immune Therapy
  168. [168]

    Ozdemir S, Caglayan R. “Health education on HPV vaccination and cervical cancer prevention: A randomised controlled trial on knowledge, attitudes, beliefs, and behaviours.” JPMA. The Journal of the Pakistan Medical Association (2026). PMID: 41830346 ↗

    L1RCTCited in: Targeted and Immune Therapy
  169. [169]

    . “Cervical Cancer Analysis Reveals New Mutations.” Cancer discovery (2017). PMID: 28179363 ↗

    L5OTHERCited in: Targeted and Immune Therapy
  170. [170]

    . “Pembrolizumab May Substantially Up Cervical Cancer Survival.” Cancer discovery (2021). PMID: 34561245 ↗

    L5OTHERCited in: Targeted and Immune Therapy
  171. [171]

    . “Pembrolizumab OK'd for Cervical Cancer.” Cancer discovery (2018). PMID: 29967015 ↗

    L5OTHERCited in: Targeted and Immune Therapy
  172. [172]

    Norberg SM, Hinrichs CS. “Engineered T cell therapy for viral and non-viral epithelial cancers.” Cancer cell (2023). PMID: 36400016 ↗

    L5REVIEW_NARRATIVECited in: Targeted and Immune Therapy
  173. [173]

    Wang X, Xiong D, Cui S et al.. “Immunoconjugates in cervical cancer: a bibliometric and thematic mapping analysis of global research trends, 2015-2024.” Frontiers in oncology (2026). PMID: 42109675 ↗

    L5SR_OBSCited in: Targeted and Immune Therapy
  174. [174]

    Ferrall L, Lin KY, Roden RBS et al.. “Cervical Cancer Immunotherapy: Facts and Hopes.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33888488 ↗

    L5REVIEW_NARRATIVECited in: Targeted and Immune Therapy
  175. [175]

    Miller KM, Friedman CF. “Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35947045 ↗

    L5OTHERCited in: Targeted and Immune Therapy
  176. [176]

    Kang Z, Stevanović S, Hinrichs CS et al.. “Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28899967 ↗

    L4OTHERCited in: Targeted and Immune Therapy
  177. [177]

    Chambers L, Haight P, Chalif J et al.. “Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-oncology Research.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38662438 ↗

    L5OTHERCited in: Targeted and Immune Therapy
  178. [178]

    Choi YW, Kang MC, Seo YB et al.. “Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27407095 ↗

    L4OTHERCited in: Targeted and Immune Therapy
  179. [179]

    Sun YY, Peng S, Han L et al.. “Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 26420854 ↗

    L4OTHERCited in: Targeted and Immune Therapy
  180. [180]

    Bae SH, Park YJ, Park JB et al.. “Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17200373 ↗

    L4OTHERCited in: Targeted and Immune Therapy
  181. [181]

    Wang J, Wang X, Xu J et al.. “Cost-effectiveness of single-dose versus two-dose HPV vaccination: a Markov cohort modelling analysis of a Kenya-India LMIC composite.” Frontiers in public health (2026). PMID: 42326956 ↗

    L2OTHERCited in: Targeted and Immune Therapy
  182. [182]

    Jerip AR, Noni V, Senian AA et al.. “Mismatch Between Vaccine Targets and Endemic HPV Genotypes in Sarawak, East Malaysia: Implications for Cervical Cancer Prevention.” Journal of medical virology (2026). PMID: 42324898 ↗

    L2OTHERCited in: Targeted and Immune Therapy
  183. [183]

    Barquin A, Kasherman L, Lheureux S et al.. “Antibody-drug conjugates in gynecologic cancers.” Cancer (2026). PMID: 42226034 ↗

    L5REVIEW_NARRATIVECited in: Targeted and Immune Therapy
  184. [184]

    Kao PY, Chen JH, Chen KH. “The Role of HPV and Hormone in Cervical Precancer and Cancer: Molecular Pathophysiology and Cell Biology of Disease and Treatment.” Oncology research (2026). PMID: 42220428 ↗

    L5REVIEW_NARRATIVECited in: Targeted and Immune Therapy
  185. [185]

    Li M, Chen Q, Wang F et al.. “Factors influencing Chongqing nurses' HPV vaccination: a cross-sectional survey based on the 5C model.” Frontiers in public health (2026). PMID: 42180508 ↗

    L4OTHERCited in: Targeted and Immune Therapy
  186. [186]

    Brand-Wiita S, Tsai CJ, Liu YH et al.. “Cost-effectiveness of pembrolizumab as a treatment for FIGO 2014 stage III-IVA cervical cancer in the United States.” Gynecologic oncology (2026). PMID: 42150374 ↗

    L2OTHERCited in: Targeted and Immune Therapy
  187. [187]

    Plačková K, Fialová A. “The immune microenvironment of HPV-associated cancers: from viral oncogenesis to immunotherapy response.” Frontiers in immunology (2026). PMID: 42148142 ↗

    L5REVIEW_NARRATIVECited in: Targeted and Immune Therapy
  188. [188]

    Monk BJ, Mas Lopez L, Zarba JJ et al.. “Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20606083 ↗

    L1RCTCited in: Toxicity and Supportive Care
  189. [189]

    Naumann RW, Hollebecque A, Meyer T et al.. “Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31487218 ↗

    L4TRIAL_NONRANDOMCited in: Toxicity and Supportive Care
  190. [190]

    Vicier C, Isambert N, Cropet C et al.. “MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors.” ESMO open (2022). PMID: 36521418 ↗

    L4TRIAL_NONRANDOMCited in: Toxicity and Supportive Care
  191. [191]

    Maschmeyer G, Fehm T, Loibl S et al.. “Onkopedia: What's New? Systemic Tumor Treatment in Pregnancy.” Oncology research and treatment (2026). PMID: 40602390 ↗

    L1GUIDELINECited in: Toxicity and Supportive Care
  192. [192]

    Strauss J, Heery CR, Schlom J et al.. “Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29298798 ↗

    L4TRIAL_NONRANDOMCited in: Toxicity and Supportive Care
  193. [193]

    Diaz-Padilla I, Duran I, Clarke BA et al.. “Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.” Cancer treatment reviews (2012). PMID: 22381585 ↗

    L5REVIEW_NARRATIVECited in: Toxicity and Supportive Care
  194. [194]

    Zhuang Q, Liu Y. “Efficacy and safety of Cadonilimab in the treatment of recurrent/metastatic and advanced cervical cancer: a systematic review and meta-analysis.” Frontiers in immunology (2025). PMID: 41601625 ↗

    L2SR_OBSCited in: Toxicity and Supportive Care
  195. [195]

    Zhang Z, Yu J, Zhang Z et al.. “The Safety of Cadonilimab: A Systematic Review and Single-Arm Meta-Analysis.” Cancer medicine (2025). PMID: 40899424 ↗

    L2SR_OBSCited in: Toxicity and Supportive Care
  196. [196]

    Kitami K, Kuji S, Kamiya N et al.. “Real-world safety and efficacy of immune checkpoint inhibitors in Japanese patients with persistent, recurrent, or metastatic cervical cancer: a multicenter prospective and retrospective study.” International journal of clinical oncology (2026). PMID: 41504989 ↗

    L2COHORTCited in: Toxicity and Supportive Care, Special Populations
  197. [197]

    Da Silva DM, Enserro DM, Mayadev JS et al.. “Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32816895 ↗

    L4OTHERCited in: Toxicity and Supportive Care
  198. [198]

    Reid E, Suneja G, Ambinder RF et al.. “AIDS-Related Kaposi Sarcoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30787130 ↗

    L1GUIDELINECited in: Special Populations
  199. [199]

    Guiguet M, Boué F, Cadranel J et al.. “Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.” The Lancet. Oncology (2009). PMID: 19818686 ↗

    L2COHORTCited in: Special Populations
  200. [200]

    Palefsky JM, Lee JY, Jay N et al.. “Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.” The New England journal of medicine (2022). PMID: 35704479 ↗

    L1RCTCited in: Special Populations
  201. [201]

    Ayeni OA, Mmereki D, Mistry H et al.. “Disease characteristics, treatment, and overall survival outcomes of patients with locally advanced cervical cancer referred for radiation therapy in Johannesburg, South Africa: a 2-year retrospective study.” BMC women's health (2026). PMID: 42310589 ↗

    L2COHORTCited in: Special Populations
  202. [202]

    Amubuomombe PP, Itsura P, Tonui PK et al.. “Pregnancy outcomes among women with and without HIV infections who underwent excisional treatment for high-grade cervical intraepithelial neoplasia: a retrospective cohort study in low-resource settings.” BMJ open (2026). PMID: 41708173 ↗

    L2COHORTCited in: Special Populations
  203. [203]

    Asare M, Ebu Enyan NI, Sencherey VL et al.. “Culturally adapting and evaluating an evidence-based communication intervention with HPV self-sampling to improve cervical cancer screening among women living with HIV in Ghana: a mixed-methods study.” BMJ open (2025). PMID: 41475829 ↗

    L4RCTCited in: Special Populations
  204. [204]

    Kabarambi A, Kizito S, Girma AZ et al.. “Preliminary Impact of Public Health Messaging on HPV Vaccine Uptake Among Adolescent Girls and Young Women Living with HIV in Central Uganda.” AIDS and behavior (2026). PMID: 41251868 ↗

    L1RCTCited in: Special Populations
  205. [205]

    Waldecker M, Taghavi K, Pasin C et al.. “Factors associated with uptake of gynaecological care and cervical cancer screening among women in the Swiss HIV Cohort Study.” HIV medicine (2025). PMID: 41216952 ↗

    L2COHORTCited in: Special Populations
  206. [206]

    Wang X, Wu Y, Huang J et al.. “Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study.” Cancer immunology, immunotherapy : CII (2025). PMID: 41136631 ↗

    L2COHORTCited in: Special Populations
  207. [207]

    Pellegrino RA, Tu S, Ville-Benavides R et al.. “Incidence and outcomes of anal and cervical cancer among adults with HIV in Latin America: a retrospective cohort study.” Journal of the International AIDS Society (2025). PMID: 41074705 ↗

    L2COHORTCited in: Special Populations
  208. [208]

    D'Souza G, Gross ND, Pai SI et al.. “Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 24778397 ↗

    L4OTHERCited in: Special Populations
  209. [209]

    McGee-Avila JK, Suneja G, Engels EA et al.. “Cancer Treatment Disparities in People With HIV in the United States, 2001-2019.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38513161 ↗

    L2OTHERCited in: Special Populations
  210. [210]

    Rose PG, Java J, Whitney CW et al.. “Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732170 ↗

    L2OTHERCited in: Special Populations
  211. [211]

    Yarchoan R, Uldrick TS. “HIV-Associated Cancers and Related Diseases.” The New England journal of medicine (2018). PMID: 29539283 ↗

    L5REVIEW_NARRATIVECited in: Special Populations

Revision History

All updates applied to this page

Loading revisions…